Related Experiment Video
Updated: May 24, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Rapid development of acute monocytic leukemia (AML-M5b) with t(9;11)(p22;q23) after chemotherapy for T-cell
Jiao Cai1, Nan Zhang1, Ling Qiu1
1Department of Hematology, Chinese People's Liberation Army The General Hospital of Western Theater Command, Chengdu, SiChuan, 610083, China.
Objective:
To investigate the diagnosis and treatment of T lymphoblastic lymphoma (T-LBL) progressing into acute monocytic leukemia (AML-M5b) and explore possible pathogenic mechanisms.
Methods:
Comprehensive diagnosis and evaluation of the patient's disease status were conducted through lymph node biopsy, bone marrow aspiration and biopsy, PET/CT, immunohistochemistry, flow cytometry, fusion gene detection, and whole-exome sequencing (WES) based on the clinical manifestations at different stages.
Results:
The lymph node biopsy revealed Ki67 positivity at 80 % and expression of TDT, CD4, CD8, CD3, and CD5. The PET/CT scan showed increased FDG metabolism at multiple sites. Based on relevant tests and examination results, the patient was diagnosed with T-LBL (stage IV; IPI score, 3). After three cycles of chemotherapy, abnormal immature monocytes were detected using bone marrow flow cytometry, suggesting an acute progression from T-LBL to AML-M5b. Chromosomal karyotype analysis revealed t(9; 11)(p22; q23) and the MLL-AF9 fusion gene. WES analysis identified mutations in several genes, among which mutations in SET domain-containing protein 2 and CBL may be associated with the occurrence of acute myeloid leukemia. The patient died 1 month after AML-M5b diagnosis.
Conclusion:
Patients with T-LBL progression to AML have a poor prognosis and shorter overall survival. Hence, exploring the pathogenic mechanisms and reasons for disease progression has significant implications for finding effective treatment modalities and prolonging patient survival.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
06:51Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Related Concept Videos
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...